Raymond James Financial Inc. Makes New $34,000 Investment in Fractyl Health, Inc. (NASDAQ:GUTS)

Raymond James Financial Inc. bought a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 16,400 shares of the company’s stock, valued at approximately $34,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Geode Capital Management LLC increased its holdings in shares of Fractyl Health by 166.5% in the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock worth $1,269,000 after acquiring an additional 313,335 shares during the period. State Street Corp grew its position in Fractyl Health by 129.4% in the 3rd quarter. State Street Corp now owns 113,415 shares of the company’s stock worth $287,000 after purchasing an additional 63,968 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Fractyl Health by 56.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after purchasing an additional 29,262 shares during the period. Conservest Capital Advisors Inc. acquired a new stake in shares of Fractyl Health in the fourth quarter valued at approximately $132,000. Finally, Barclays PLC raised its holdings in shares of Fractyl Health by 1,754.7% during the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock valued at $121,000 after buying an additional 45,219 shares during the last quarter.

Insider Activity

In other Fractyl Health news, insider Jay David Caplan sold 22,346 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $1.81, for a total value of $40,446.26. Following the completion of the sale, the insider now directly owns 153,544 shares in the company, valued at $277,914.64. This represents a 12.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Harith Rajagopalan sold 90,972 shares of Fractyl Health stock in a transaction on Friday, January 31st. The shares were sold at an average price of $1.82, for a total value of $165,569.04. Following the transaction, the chief executive officer now owns 491,329 shares in the company, valued at approximately $894,218.78. This trade represents a 15.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Fractyl Health Price Performance

Shares of GUTS opened at $1.01 on Monday. Fractyl Health, Inc. has a one year low of $0.87 and a one year high of $7.89. The stock’s fifty day moving average is $1.34 and its 200-day moving average is $1.91. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The firm has a market capitalization of $49.41 million, a price-to-earnings ratio of -0.08 and a beta of 0.30.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). Equities analysts anticipate that Fractyl Health, Inc. will post -1.61 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley decreased their price objective on Fractyl Health from $18.00 to $10.00 and set an “overweight” rating for the company in a report on Monday, February 3rd.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.